IDEAYA Biosciences, Inc. Income Statement
IDYA / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
IDEAYA Biosciences, Inc. reported $219M in revenue and $114M in net loss for FY2025. Revenue has grown at a 62.1% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 4.55 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M | $19.5M | $0 | - | - |
| SG&A Expense | $63.3M | $39.3M | $28.3M | $23.9M | $20.1M | $4.7M | $10.0M | $4.7M | $2.1M |
| R&D Expense | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M | $31.7M | $34.3M | $31.7M | $12.4M |
| Operating Income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M | -$36.4M | -$44.3M | -$36.4M | -$14.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M | -$34.3M | -$42.0M | -$34.3M | -$11.9M |
| EPS (Basic) | -$1.28 | -$3.36 | -$1.96 | -$1.42 | -$1.41 | - | - | - | - |
| EPS (Diluted) | -$1.28 | -$3.36 | -$1.96 | -$1.42 | -$1.41 | -$35.92 | - | - | - |
| Shares Outstanding | 87.8M | 86.5M | 65.0M | 48.2M | 38.5M | 20.3M | 12.5M | 956.3K | 695.4K |
| Operating Margin | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | -186.4% | - | - | - |
| Profit Margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | -175.8% | - | - | - |